Metformin Teva B.V.

Metformin Hydrochloride, the active ingredient in Metformin Teva B.V., is a biguanide presented as an oral tablet for oral use. It helps lower elevated blood glucose levels by targeting hepatic glucose output and improving peripheral insulin sensitivity, and it is indicated for the management of type 2 diabetes mellitus as well as off‑label use in insulin‑resistant conditions.

GNH USA supplies Metformin Teva B.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is manufactured under strict Good Manufacturing Practice guidelines.

Metformin is an oral antidiabetic agent that acts on glucose metabolism in type 2 diabetes and related insulin‑resistant states.

Type 2 diabetes mellitus: improves glycemic control by reducing hepatic glucose production and enhancing peripheral glucose uptake. Polycystic ovary syndrome: may improve insulin sensitivity and restore ovulatory function in affected women. Impaired glucose tolerance: helps delay progression to overt diabetes by improving insulin action.

Metformin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: watery stools occurring especially after dose initiation. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Vitamin B12 deficiency: may develop with long‑term therapy. - Hepatic dysfunction: rare elevation of liver enzymes or hepatitis.

Before initiating Metformin, several safety considerations should be evaluated. - Renal function assessment: ensure eGFR ≥30 mL/min/1.73 m² before starting. - Hepatic function monitoring: avoid use in patients with active liver disease. - Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia (e.g., heart failure, severe infection). - Concomitant alcohol use: limit intake as alcohol can increase lactic acidosis risk. - Dose adjustments in the elderly: start with lower doses and titrate cautiously. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin’s pharmacokinetics can be altered by several co‑administered medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise Metformin plasma concentrations. - Alcohol intoxication: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors or ARBs: can affect renal function, requiring monitoring of eGFR. - Thiazide diuretics: may increase risk of hypoglycemia when combined with insulin secretagogues.